Výsledky vyhledávání - "Louvina E. van der Laan"

Akademický článek

Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis

Autor: Louvina E. van der Laan, Anthony J. Garcia-Prats, H. Simon Schaaf, Jana L. Winckler, Heather Draper, Jennifer Norman, Lubbe Wiesner, Helen McIlleron, Paolo Denti, Anneke C. Hesseling

Publikováno v: Frontiers in Pharmacology, Vol 12 (2021)

Given the high prevalence of multidrug-resistant (MDR)-TB in high HIV burden settings, it is important to identify potential drug-drug interactions between MDR-TB treatment and widely used nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-po

Externí odkaz: https://doaj.org/article/0efbb15ebb8e4f389d9763f01fa80e8a

Zobrazit plný text záznamu

Akademický článek

HPV serostatus pre- and post-vaccination in a randomized phase II preparedness trial among young Western Cape, South African women: The evri trial

Autor: Staci L. Sudenga, B. Nelson Torres, Matthys H. Botha, Michele Zeier, Martha E. Abrahamsen, Richard H. Glashoff, Susan Engelbrecht, Maarten F. Schim Van der Loeff, Louvina E. Van der Laan, Siegfried Kipping, Douglas Taylor, Anna R. Giuliano

Publikováno v: Papillomavirus Research, Vol 3, Iss , Pp 50-56 (2017)

Background: HPV antibodies are a marker of past exposure to the virus. Our objective was to assess HPV serostatus pre- and post-vaccination among HIV-negative women. Methods: Women aged 16â24 years old were randomized in a placebo controlled trial u

Externí odkaz: https://doaj.org/article/aae693d382134c899706bfad3397616f

Zobrazit plný text záznamu

Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children

Autor: Anneke C. Hesseling, Barend Fourie, Jana Winckler, H. Simon Schaaf, Anthony J Garcia-Prats, James C. Nielsen, Belén P. Solans, Stephanie Thee, Lubbe Wiesner, Louvina E van der Laan, Radojka M. Savic, Heather R. Draper, Kendra K. Radtke

Publikováno v: Clin Infect Dis

Background Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86403823ca107e0946d6865f749711d2
https://doi.org/10.1093/cid/ciab641

Zobrazit plný text záznamu

Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis

Autor: Louvina E. van der Laan, Anthony J. Garcia-Prats, H. Simon Schaaf, Maxwell Chirehwa, Jana L. Winckler, Jun Mao, Heather R. Draper, Lubbe Wiesner, Jennifer Norman, Helen McIlleron, Peter R. Donald, Anneke C. Hesseling, Paolo Denti

Publikováno v: Antimicrob Agents Chemother

Treatment options for children with Rifampicin-resistant tuberculosis (RR-TB) remain limited, and para-aminosalicylic acid (PAS) is still a relevant component of treatment regimens. Prevention of resistance to companion drugs by PAS is dose related,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4db868fe7b28d262dc472fd750dfb445
https://pubmed.ncbi.nlm.nih.gov/35506699

Zobrazit plný text záznamu

Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study

Autor: Lubbe Wiesner, Jana Winckler, Roeland E Wasmann, Annelies Van Rie, Heather J. Zar, Elin M. Svensson, Louvina E. van der Laan, Helena Rabie, Helen McIlleron, Anneke C. Hesseling, Paolo Denti, Adrie Bekker, Carmen Gonzalez-Martinez, Gerry Davies

Publikováno v: Clin Infect Dis
Clinical Infectious Diseases, 75, 141-151
CLINICAL INFECTIOUS DISEASES
Clinical Infectious Diseases, 75, 1, pp. 141-151
Clinical infectious diseases

Background In 2010, the World Health Organization (WHO) revised dosing guidelines for treatment of childhood tuberculosis. Our aim was to investigate first-line antituberculosis drug exposures under these guidelines, explore dose optimization using t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76fa0853f3cbea950b899b3dda6d7bea
https://doi.org/10.1093/cid/ciab908

Zobrazit plný text záznamu

Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis

Autor: Kendra K. Radtke, Elin M. Svensson, Louvina E. van der Laan, Anneke C. Hesseling, Radojka M. Savic, Anthony J. Garcia-Prats

Publikováno v: Expert Review of Clinical Pharmacology, 15, 2, pp. 161-174
Expert Review of Clinical Pharmacology, 15, 161-174

Item does not contain fulltext INTRODUCTION: Despite its longstanding role in tuberculosis (TB) treatment, there continues to be emerging rifampicin research that has important implications for pediatric TB treatment and outstanding questions about i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1abdc88fc9825a51e2757a2245da0f9
https://doi.org/10.1080/17512433.2022.2053110

Zobrazit plný text záznamu

Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

Autor: H. Simon Schaaf, Jana Winckler, Anthony J Garcia-Prats, Lee Fairlie, Masebole Masenya, Anneke C. Hesseling, Paolo Denti, Mats O. Karlsson, Heather R. Draper, Louvina E van der Laan, Jennifer Norman, Rob E. Aarnoutse, Elin M. Svensson, Lubbe Wiesner

Publikováno v: J Antimicrob Chemother
Journal of Antimicrobial Chemotherapy, 76, 3237-3246
Journal of Antimicrobial Chemotherapy, 76, 12, pp. 3237-3246

BackgroundRifampicin doses of 40 mg/kg in adults are safe and well tolerated, may shorten anti-TB treatment and improve outcomes, but have not been evaluated in children.ObjectivesTo characterize the pharmacokinetics and safety of high rifampicin dos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a35330d85bb763af33aa6384574411b
https://pubmed.ncbi.nlm.nih.gov/34529779

Zobrazit plný text záznamu

HPV serostatus pre- and post-vaccination in a randomized phase II preparedness trial among young Western Cape, South African women: The evri trial

Autor: Louvina E. van der Laan, Richard H. Glashoff, Anna R. Giuliano, Douglas Taylor, B. Nelson Torres, Susan Engelbrecht, M H Botha, Staci L. Sudenga, Michele Zeier, Maarten F Schim van der Loeff, Martha Abrahamsen, Siegfried Kipping

Publikováno v: Papillomavirus Research, Vol 3, Iss, Pp 50-56 (2017)
Papillomavirus Research

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96c6e25667b653d0772d7c6138cc94f

Zobrazit plný text záznamu

Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial

Autor: Lynette Menezes, Ubin Pokharel, Richard H. Glashoff, Louvina E. van der Laan, Martha Abrahamsen, Staci L. Sudenga, Susan Engelbrecht, Douglas Taylor, Siegfried Kipping, Anna R. Giuliano, Michele Zeier, M H Botha, Maarten F Schim van der Loeff

Publikováno v: Sexually Transmitted Infections. 94:55-61

ObjectiveTo estimate the prevalence and describe the patterns of concurrent human papillomavirus (HPV) and STIs and associated factors among HIV-negative young Western Cape, South African women participating in the Efficacy of HPV Vaccine to Reduce H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f900be880c5b654d07e757fbf329d80d
https://doi.org/10.1136/sextrans-2016-053046

Zobrazit plný text záznamu

Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial

Autor: Maarten F Schim van der Loeff, M H Botha, Martha Abrahamsen, Douglas Taylor, Susan Engelbrecht, Louvina E. van der Laan, Staci L. Sudenga, Michele Zeier, Siegfried Kipping, Richard H. Glashoff, Anna R. Giuliano, B. Nelson Torres

Publikováno v: Journal of infection, 72(1), 60-69. W.B. Saunders Ltd

Summary Objective The objective of this analysis was to assess human papillomavirus (HPV) infection persistence and incidence 7-months post-enrollment by HPV vaccine study arm (vaccine or placebo). Methods HIV-negative, sexually active women aged 16�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd48104167508a95e551301bcad6be20
https://doi.org/10.1016/j.jinf.2015.10.001

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání